Anti-epidermal growth factor receptor siRNA carried by chitosan-transacylated lipid nanocapsules increases sensitivity of glioblastoma cells to temozolomide

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 1479-1490

  Messaoudi, Khaled ^a   Saulnier, Patrick ^a   Boesen, Kim ^a   Benoit, Jean Pierre ^a,b   Lagarce, Frederic ^a,b  

^a Laboratoire d'Acoustique Environnementale   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Chitosan; EGFR; Glioblastoma; Lipid nanocapsules; siRNA; Temozolomide

Indexed keywords

CHITOSAN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUORESCEIN ISOTHIOCYANATE; NANOCAPSULE; SMALL INTERFERING RNA; TEMOZOLOMIDE;

ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HYDRODYNAMICS; IONIZATION; LIGHT SCATTERING; MORTALITY; PARTICLE SIZE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN SYNTHESIS; PURIFICATION; ZETA POTENTIAL;

CHITOSAN; EGFR; GLIOBLASTOMA; LIPID NANOCAPSULES; SIRNA; TEMOZOLOMIDE;

ACYLATION; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; CHITOSAN; DACARBAZINE; DRUG SYNERGISM; GENE SILENCING; GLIOBLASTOMA; HUMANS; LIPIDS; NANOCAPSULES; PARTICLE SIZE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING; TREATMENT OUTCOME;

EID: 84897038173     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S59134     Document Type: Article

References (43)

1. Lefranc F, Sadeghi N, Camby I, Metens T, Dewitte O, Kiss R. Present and potential future issues in glioblastoma treatment. Expert Rev Anticancer Ther. 2006;6(5):719-732.
2. Stupp R, Mason WP, van den Bent MJ, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
3. Stupp R, Hegi ME, Mason WP, et al. European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
4. Le Mercier M, Fortin S, Mathieu V, Kiss R, Lefranc F. Galectins and gliomas. Brain Pathol. 2010;20(1):17-27.
5. Mao XG, Yan M, Xue XY, et al. Overexpression of ZNF217 in glioblastoma contributes to the maintenance of glioma stem cells regulated by hypoxia-inducible factors. Lab Invest. 2011;91(7): 1068-1078.
6. Zhu D, Hunter SB, Vertino PM, Van Meir EG. Overexpression of MBD2 in glioblastoma maintains epigenetic silencing and inhibits the antiangiogenic function of the tumor suppressor gene BAI1. Cancer Res. 2011;71(17):5859-5870.
7. Huang PH, Xu AM, White FM. Oncogenic EGFR signaling networks in glioma. Sci Signal. 2009;2(87):re6.
8. Guha A, Feldkamp MM, Lau N, Boss G, Pawson A. Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene. 1997;15(23):2755-2765.
9. Narita Y, Nagane M, Mishima K, Huang HJ, Furnari FB, Cavenee WK. Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res. 2002;62(22):6764-6769.
10. Furuta S, Hidaka E, Ogata A, Yokota S, Kamata T. Ras is involved in the negative control of autophagy through the class I PI3-kinase. Oncogene. 2004;23(22):3898-3904.
11. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst. 2005;97(12):880-887.
12. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806-811.
13. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet. 2002;3(10):737-747.
14. Ngo H, Tschudi C, Gull K, Ullu E. Double-stranded RNA induces mRNA degradation in Trypanosoma brucei. Proc Natl Acad Sci U S A. 1998;95(25):14687-14692.
15. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev. 2007;59(2-3):75-86.
16. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet. 2007;8(3):173-184.
17. Reischl D, Zimmer A. Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomedicine. 2009;5(1):8-20.
18. Volkov AA, Kruglova NS, Meschaninova MI, et al. Selective protection of nuclease-sensitive sites in siRNA prolongs silencing effect. Oligonucleotides. 2009;19(2):191-202.
19. Li CX, Parker A, Menocal E, Xiang S, Borodyansky L, Fruehauf JH. Delivery of RNA interference. Cell Cycle. 2006;5(18):2103-2109.
20. David S, Pitard B, Benoit JP, Passirani C. Non-viral nanosystems for systemic siRNA delivery. Pharmacol Res. 2010;62(2):100-114.
21. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118(9):3132-3142.
22. Kakizawa Y, Furukawa S, Ishii A, Kataoka K. Organic-inorganic hybrid-nanocarrier of siRNA constructing through the self-assembly of calcium phosphate and PEG-based block aniomer. J Control Release. 2006;111(3):368-370.
23. Ambruosi A, Khalansky AS, Yamamoto H, Gelperina SE, Begley DJ, Kreuter J. Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. Journal of Drug Targeting. 2006;14(2):97-105.
24. Auffinger B, Morshed R, Tobias A, Cheng Y, Ahmed AU, Lesniak MS. Drug-loaded nanoparticle systems and adult stem cells: a potential marriage for the treatment of malignant glioma? Oncotarget. 2013;4(3):378-396.
25. Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res. 2002;19(6):875-880.
26. Hureaux J, Lagarce F, Gagnadoux F, et al. Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel. Eur J Pharm Biopharm. 2009;73(2):239-246.
27. Hureaux J, Lagarce F, Gagnadoux F, et al. Toxicological study and efficacy of blank and paclitaxel-loaded lipid nanocapsules after iv administration in mice. Pharm Res. 2010;27(3):421-430.
28. Saranya N, Moorthi A, Saravanan S, Devi MP, Selvamurugan N. Chitosan and its derivatives for gene delivery. Int J Biol Macromol. 2011;48(2):234-238.
29. Perrier T, Fouchet F, Bastiat G, Saulnier P, Benoit JP. OPA quantification of amino groups at the surface of lipidic nanocapsules (LNCs) for ligand coupling improvement. Int J Pharm. 2011;419(1-2):266-270.
30. Marzolini C, Decosterd LA, Shen F, et al. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. Cancer Chemother Pharmacol. 1998;42(6):433-440.
31. Han L, Zhang AL, Xu P, et al. Combination gene therapy with PTEN and EGFR siRNA suppresses U251 malignant glioma cell growth in vitro and in vivo. Med Oncol. 2010;27(3):843-852.
32. Rudzinski WE, Aminabhavi TM. Chitosan as a carrier for targeted delivery of small interfering RNA. Int J Pharm. 2010;399(1-2):1-11.
33. Fischer D, Bieber T, Li Y, Elsasser HP, Kissel T. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res. 1999;16(8):1273-1279.
34. Lv H, Zhang S, Wang B, Cui S, Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release. 2006;114(1): 100-109.
35. Katas H, Alpar HO. Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release. 2006;115(2):216-225.
36. Katas H, Chen S, Osamuyimen AA, Cevher E, Oya Alpar H. Effect of preparative variables on small interfering RNA loaded Poly(D, L-lactide-co-glycolide)-chitosan submicron particles prepared by emulsification diffusion method. J Microencapsul. 2008;25(8):541-548.
37. Liu X, Howard KA, Dong M, et al. The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials. 2007;28(6):1280-1288.
38. Techaarpornkul S, Wongkupasert S, Opanasopit P, Apirakaramwong A, Nunthanid J, Ruktanonchai U. Chitosan-mediated siRNA delivery in vitro: effect of polymer molecular weight, concentration and salt forms. AAPS PharmSciTech. 2010;11(1):64-72.
39. Qi LF, Xu ZR, Li Y, Jiang X, Han XY. In vitro effects of chitosan nanoparticles on proliferation of human gastric carcinoma cell line MGC803 cells. World J Gastroenterol. 2005;11(33):5136-5141.
40. Le Mercier M, Mathieu V, Haibe-Kains B, et al. Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses. J Neuropathol Exp Neurol. 2008;67(5):456-469.
41. Agrawal A, Min DH, Singh N, et al. Functional delivery of siRNA in mice using dendriworms. ACS Nano. 2009;3(9):2495-2504.
42. Michiue H, Eguchi A, Scadeng M, Dowdy SF. Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma. Cancer Biol Ther. 2009;8(23):2306-2313.
43. Prados MD, Chang SM, Butowski N, et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2009;27(4):579-584.